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APPENDIX 2 (ONLINE ONLY). DECEMBER
2002 CLINICAL UPDATE VOL I: THE ANEURX
STENT GRAFT SYSTEM
This report was prepared by Medtronic AVE and ap-
proved by the FDA for distribution to physicians using the
AneuRx Stent Graft System. It has been edited to comply
with the format requirements of the Journal.
The report is divided into four sections. The first sec-
tion contains clinical endpoint data from the entire
Medtronic AVE US IDE cohort, which includes 1193
patients and data to 4 years. These data include safety
endpoints (patient mortality, rupture, surgical conversion)
as well as key endovascular measures (endoleak, aneurysm
size, migration, patency, and device integrity). The second
section summarizes information regarding aneurysm rup-
ture, surgical conversion, and mortality from our combined
global commercial experience. The third section summa-
rizes the results from our explant analyses, and the fourth
section provides summary comments. The data in this
report include information collected and analyzed as of
August 28, 2002.
Section I: Clinical trial data update
A total of 1193 patients were treated with the AneuRx
Stent Graft System at 19 US investigational centers from
1996 to 1999. These patients were enrolled in three study
phases. Phase I, consisting of 40 patients, enrolled patients
from June 1996 to April 1997. Phase II began in April
1997 and ended in September 1998, with 424 patients
enrolled and treated and one patient enrolled and not
treated (the patient experienced a myocardial infarction
after enrollment and prior to the procedure and did not
receive the stent graft). Phase III enrolled 639 patients
beginning in August 1998 and ending on September 30,
1999. Ninety additional patients not meeting the trial’s
inclusion criteria were enrolled in a high-risk arm of the
trial. These patients are included in the long-term analysis.
Sixty-six patients were also enrolled in the control arm of
the study, receiving standard surgical treatment for abdom-
inal aortic aneurysm (AAA). These patients were evaluated
for morbidity and mortality and compared with 416 Phase
II patients for premarket approval. Beyond the 1-year fol-
low-up period for these 66 patients, we have only actively
collected mortality status.
All patients in Phase I and 134 patients in Phase II (174
patients total) received a device design that incorporated a
unibody “stiff” stent in the aortic body of the device. The
remaining 1019 patients were implanted with a device
design that incorporated a multisegmented “flexible” aor-
tic body. This “flexible” device configuration is that which
is currently marketed. The data below include all 1193
patients implanted with both stiff-body and flexible devices
and include patient data through August 28, 2002.
One patient is not included in the rupture, survival, and
aneurysm-related death analyses because this patient re-
ceived a conversion device. The conversion device was
approved as a treatment arm of the investigational device
exemption (IDE) and is intended for use with the bifur-
cated device.
Table I provides a summary of clinical results relating to
rates of rupture, conversion, aneurysm-related death, and
all-cause mortality. Along with the “intraoperative”, “less
than or equal to 30 days”, and “greater than 30 days”
results, Kaplan-Meier summaries are provided for these
endpoints for each year of follow-up, out to 4 years. A
breakdown of the number of patients followed through
each follow-up period for the clinical data presented in this
report is provided in Table XII.
Tables II and III outline the primary causes of conver-
sion and the primary categories of aneurysm-related death
provided in Table I.
Table I. Rupture, conversion, and death
Intraoperative
n (%)
30 days*
n (%)
30 days
n† Total† n
Kaplan-
Meier
summaries
1-year
Kaplan-
Meier
2-year
Kaplan-
Meier
3-year
Kaplan-
Meier
4-year
Kaplan-
Meier
Aneurysm rupture 2/1193
(0.17%)
3/1193
(0.25%)
10/1193 15/1193 Freedom from
aneurysm
Rupture
99.5% 98.5% 98.4% 98.4%
Conversion to
surgical repair
11/1193
(0.92%)
4/1193
(0.34%)
38/1193 53/1193 Freedom from
conversion
98.5% 96.9% 94.2% 90.4%
Aneurysm-related
death‡
0 22/1193
(1.8%)
8/1193 30/1193 Freedom from
aneurysm-related
death
98.2% 97.5% 96.9% 96.9%
Death (all-cause) 0 22/1193
(1.8%)
228/1193 250/1193 Probability of
survival (based
on all-cause
mortality)
91.8% 83.1% 76.6% 62.4%
*Postoperative, but within 30 days.
†Patients within this group are currently at a variety of follow-up periods; therefore, rates are not given for these columns. Please refer to Kaplan-Meier estimates
for specific projections for patients  30 days postprocedure.
‡Aneurysm-related death is defined as any death occurring within 30 days of the initial treatment, a rupture, a conversion, or any other secondary stent graft
procedure.
Kaplan-Meier analyses of device performance during
the US IDE trial are provided in Tables IV through VII.
Kaplan-Meier curves for this data analysis are shown in Figs
1 through 4 (print). Please note that there are too few
patients at this time to draw any valid statistical conclusions
for the 5-year probability.
Ruptures: Kaplan-Meier analysis. As demonstrated
in Table IV, patients treated with the AneuRx stent graft
have a 4-year freedom from rupture rate of 98.4%.
Surgical conversion: Kaplan-Meier analysis. As
demonstrated in Table V, patients treated with the AneuRx
stent graft have a 4-year freedom from surgical conversion
rate of 90.4%.
Aneurysm-related death: Kaplan-Meier analysis.
Aneurysm-related death is defined as any death occurring
within 30 days of the initial treatment, a rupture, a conver-
sion, or any other secondary stent graft procedure. As
demonstrated in Table VI, patients treated with the An-
euRx stent graft have a 4-year freedom from aneurysm-
related death rate of 96.9%.
Mortality (all cause): Kaplan-Meier analysis. As
demonstrated in Table VII, patients treated with the An-
euRx stent graft have a 4-year probability of survival (based
on all-cause mortality) of 62.4%.
Other outcome measures. The data presented in Ta-
ble VIII contain hospital data as defined by the investigat-
ing physician. The decrease in denominators over time is
mostly attributed to patients not having reached that fol-
low-up period. The decrease could also be attributed to the
data point not having been collected at the visit or the
patient missing the follow-up visit.
Core lab (Phase II patients)/hospital observations
for device integrity. As part of the clinical study and
routine follow-up, data were analyzed for “device integri-
ty”. This endpoint was based on core lab determination of
the device displaying a stent fracture or (probable/possi-
ble) suture pop.
A total of 75 clinical trial patients had one or more
device integrity reports. Forty-six Phase II patients had one
or more device integrity reports as demonstrated by the
core lab; seven patients did not have core lab reports but
had noted hospital findings for possible stent graft integrity
issues. Twenty-two Phase III patients had hospital reports
only, as core lab evaluation was not required for Phase III.
Core lab evaluations were based on review of plain abdom-
inal radiographs for mostly Phase II patients (protocol
requirement). The core lab device integrity report observa-
tions include the following: 39 unconfirmed or possible
“suture pop” (also described as “step off”); 8 endoleaks (of
questionable origin or existence); 3 appearances of migra-
tion of the stent graft; 1 note of separation of “cranial
position” of the graft; 1 note of iliac limb separation; 4
possible stent graft fractures (with no fracture noted by
hospital assessment); and 8 reports of “cannot determine”
device integrity. Individual patients could have more than
one observation.
Of the 46 patients with core lab evaluations, 40 patients
had hospital reports of “no device integrity issue noted,”
and 6 patients had possible graft integrity issues recorded as
“yes” on the hospital case report forms (3 reports of “graft
wall defect, tear, or disruption”; 1 report of “attachment
system fracture”; 1 report of “possible material defect in the
right collateral limb”; and 1 report of suture pop). One
patient with a report of graft wall defect underwent surgical
conversion for endoleak and AAA expansion, and one
patient had additional iliac limbs implanted to treat a per-
sistent endoleak. None of the remaining four patients with
both a core lab and hospital integrity concern had had an
additional procedure of any kind.
Of the total patients with a device integrity report of
any kind, six patients underwent successful surgical conver-
sions. Two of these conversions were elective. Of the four
remaining patients, two patients did not have confirmed
loss of device integrity by either hospital or core lab find-
ings.
During the successful surgical conversion procedure,
one of the patients exhibited some blood flow through the
stent graft, which had migrated due to lack of oversizing
per the instructions for use. The aortic neck was observed to
be thrombosed and calcified, which likely had a deleterious
effect on the proximal seal. No stent ring fractures were
observed. Some weave separation, minimal graft abrasion,
and suture breaks were observed in the explanted device.
This device did not contain the tighter fabric weave con-
tained in the currently commercialized product.
The second patient was considered to have stent graft
integrity issues as evidenced by hospital assessment and an
endoleak of questionable origin as noted by the core lab
report. At 2-year follow-up, this patient presented with
Table II. Primary causes of conversion
Cause n
Endoleak w/AAA expansion 18
Rupture 11
Migration/displacement of modular component 11
Failure to access 7
AAA expansion 2
Endoleak 1
Other (pseudoaneurysm, aortic fistula, aneurysm pressing
on colon)
3
Total 53
Table III. Primary categories of aneurysm-related
death*
Category n
Within 30 days of initial treatment 18
Within 30 days of rupture 4
Within 30 days of surgical conversion 7
Within 30 days of secondary stent graft procedure 1
Total 30
*Aneurysm-related death is defined as any death occurring within 30 days of
the initial treatment, a rupture, a conversion, or any other secondary stent
graft procedure.
abdominal pain radiating to the back. The aneurysm diam-
eter had increased with evidence of a persistent endoleak.
Type II endoleaks were noted at predischarge, 1-month CT
scan, and 1-year CT scan, and coil embolization of the
inferior mesenteric artery was performed during the fol-
low-up period. During surgical conversion, a leak was
noted in the contralateral limb. Upon explant, one fatigue
fracture was noted which was not in the seal zone, and
weave separation and suture breaks were also observed. The
weave separation, noted on the contralateral limb of the
explanted device, is likely related to the leak observed
during surgical conversion. The patient was successfully
Table IV. Ruptures: Summary of Kaplan-Meier analysis*
Treatment to
6 months
6 months to
1 year
1 year to
2 years
2 years to
3 years
3 years to
4 years
No. at risk† 1193¶ 1116 1002 714 292
No. of events 5 1 8 1 0
No. of censored‡ 72 113 280 421 251
Cumulative censored§ 72 185 465 886 1137
Kaplan-Meier estimate 0.996 0.995 0.985 0.984 0.984
Standard error 0.0019 0.0021 0.0039 0.0044 0.0044
*For additional information on the number of patients followed at these time intervals, please refer to Table XII.
†Number of patients at risk at the beginning of interval (based on actual implantation duration).
‡Patients are censored because their last follow-up has not reached the end of the time interval, due to all-cause death, due to surgical conversion, or because
they are lost to follow-up.
§The total censored for all time intervals up to and including that specific time interval.
Estimate made at end of time interval.
¶One patient is not included. This patient received a conversion device.
Table V. Surgical conversion: Summary of Kaplan-Meier analysis*
Treatment to
6 months
6 months to
1 year
1 year to
2 years
2 years to
3 years
3 years to
4 years
No. at risk† 1193¶ 1105 998 712 293
No. of events 16 2 14 14 6
No. censored‡ 72 105 272 405 244
Cumulative censored§ 72 177 449 854 1098
Kaplan-Meier estimate 0.987 0.985 0.969 0.942 0.904
Standard error 0.0034 0.0036 0.0056 0.0089 0.0177
*For additional information on the number of patients followed at these time intervals, please refer to Table XII.
†Number of patients at risk at the beginning of interval (based on actual implantation duration).
‡Patients are censored because their last follow-up has not reached the end of the time interval, due to all-cause death, due to surgical conversion, or because
they are lost to follow-up.
§The total censored for all time intervals up to and including that specific time interval.
Estimate made at end of time interval.
¶One patient is not included. This patient received a conversion device.
Table VI. Aneurysm-related death: Summary of Kaplan-Meier analysis*
Treatment to
6 months
6 months to
1 year
1 year to
2 years
2 years to
3 years
3 years to
4 years
No. at risk† 1193¶ 1112 999 709 291
No. of events 22 0 5 3 0
No. censored‡ 59 113 285 415 249
Cumulative censored§ 59 172 457 872 1121
Kaplan-Meier estimate 0.982 0.982 0.975 0.969 0.969
Standard error 0.0039 0.0039 0.0047 0.0059 0.0059
*For additional information on the number of patients followed at these time intervals, please refer to Table XII.
†Number of patients at risk at the beginning of interval (based on actual implantation duration).
‡Patients are censored because their last follow-up has not reached the end of the time interval, due to all-cause death, due to surgical conversion, or because
they are lost to follow-up.
§The total censored for all time intervals up to and including that specific time interval.
Estimate made at end of time interval.
¶One patient is not included. This patient received a conversion device.
converted; however, he expired 10 days later due to respi-
ratory failure.
The third patient had “modular disconnection” at 2
years by hospital assessment. At 28 months, the patient had
a successful open repair because the proximal neck was too
short to permit endovascular treatment. The explant anal-
ysis notes two fatigue fractures in the bifurcated segment
and one fatigue fracture in the aortic cuff (none were in the
seal zone, so they probably were not the cause of migra-
tion), an abrasion hole at the crown edge (totally obscured
by tissue without evidence of leakage in the adjacent tissue),
and consecutive suture breaks in the distal iliac cuff limb
(not likely a cause of proximal endoleak).
The fourth patient had a successful surgical conversion
at 25 months. The hospital assessment at 2 years was
“modular disconnection”. Angiogram revealed separation
between the stent body and the cuff. There was evidence of
a Type III endoleak, modular component disconnect, and
evidence of separation of stent rings. Further assessment
noted that the aortic extension cuff was implanted in an
angled neck. This angle was also associated with the im-
plant of the bifurcated segment. During explant analysis,
stent fractures, graft abrasion, and suture breaks were ob-
served.
Of the remaining patients, 21 underwent an additional
procedure (additional stent graft component placed, coil
embolization or ligation of arteries for treatment of Type II
endoleaks, or Dacron taping via aneurysmorrhaphy) for any
reason. The remaining 48 patients did not require any
additional procedure.
Careful patient selection and appropriate follow-up are
important factors for success with endovascular stent graft-
ing. The recently updated AneuRx Stent Graft Instructions
for Use outlines the following critical factors for successful
clinical outcomes:
● Appropriate patient selection, including a 15-mm aortic
seal zone and 25-mm iliac seal zones and aortic neck
angulation of 45 degrees;
● 10% to 20% oversizing;
● effective device deployment in accordance with the in-
structions for use;
● appropriate and timely patient follow-up.
Section II: Commercial experience/product
performance update
As of August 30, 2002, more than 25,000 AneuRx
devices have been distributed worldwide. From this com-
mercial experience, Medtronic AVE gathered product per-
formance information via field reports as well as from the
active product and explant analysis programs. Table IX
summarizes all reports received from commercial experi-
ence with the AneuRx Stent Graft through August 30,
2002.
Table VII. Mortality (all cause): Summary of Kaplan-Meier analysis*
Treatment to
6 months
6 months to
1 year
1 year to
2 years
2 years to
3 years
3 years to
4 years
No. at risk† 1193¶ 1111 999 708 291
No. of events 61 35 87 38 24
No. censored‡ 21 77 204 379 225
Cumulative censored§ 21 98 303 681 906
Kaplan-Meier estimate 0.948 0.918 0.831 0.766 0.624
Standard error 0.0064 0.0080 0.0115 0.0147 0.0305
*For additional information on the number of patients followed at these time intervals, please refer to Table XII.
†Number of patients at risk at the beginning of interval (based on actual implantation duration).
‡Patients are censored because their last follow-up has not reached the end of the time interval, due to all-cause death, due to surgical conversion, or because
they are lost to follow-up.
§The total censored for all time intervals up to and including that specific time interval.
Estimate made at end of time interval.
¶One patient is not included. This patient received a conversion device.
Table VIII. Other measures (or “efficacy outcomes”)
Predischarge
n (%)
1 month
n (%)
6 months
n (%)
1 year
n (%)
2 years
n (%)
3 years
n (%)
4 years
n (%)
Endoleak 306/1103
(27.7%)
147/1056
(13.9%)
135/987
(13.7%)
132/951
(13.9%)
129/772
(16.7%)
63/451
(14.0%)
19/137
(13.9%)
Enlarged
aneurysm*
N/A 48/523
(9.2%)
41/710
(5.8%)
48/689
(7.0%)
46/551
(8.3%)
39/346
(11.3%)
15/130
(11.5%)
Prosthesis
migration
N/A 3/947
(0.3%)
10/920
(1.1%)
20/904
(2.2%)
39/732
(5.3%)
32/449
(7.1%)
13/137
(9.5%)
Patency 1105/1106
(99.9%)
1036/1041
(99.5%)
972/978
(99.4%)
945/953
(99.2%)
762/773
(98.6%)
443/451
(98.2%)
132/137
(96.4%)
*This endpoint is defined as any increase  5mm as compared to pre-discharge measurement.
Section III: Explant analyses
Medtronic AVE has analyzed AneuRx devices that were
implanted and subsequently explanted either at surgery or
at autopsy. As of August 30, 2002, Medtronic AVE has
completed and submitted to the FDA individual case anal-
yses (including summary reports and individual case re-
ports) on 115 explants from patients implanted worldwide
(Table X) from 1996 to 2002. A summary of these 115
explants is provided in the following pages.
Each explanted device received by Medtronic AVE is
scientifically evaluated by Medtronic AVE personnel as well
as outside technical experts where appropriate. The detailed
findings are then evaluated in conjunction with the patient-
specific clinical information to assess the potential clinical
significance, if any, of the device findings. Patient anatomy
and the procedural technique used by the physician are also
assessed. Findings are presented to the implanting physi-
cian and appropriate regulatory bodies, including the FDA.
Explant summary of observations. The Figure
shows the distribution of implant duration for these 115
explants. The explants had been implanted for an average of
16.9 months. Ninety-five of 115 explants (83%) had been
implanted for more than 1 month.
Table XI shows the primary reasons for explant as
determined by the treating or explanting physician. Periop-
erative implants (1 month) and longer-term explants (1
month) are given separately.
Explant device observations. As part of an individual
analysis of each explanted device, the integrity of the com-
ponents of the stent graft is examined. This examination
includes the stents, graft material, and sutures.
Stent observations. Nitinol stent strut fractures have
been observed in devices that have been surgically ex-
planted as well as removed at autopsy. Fractures can be
categorized as due to single event overload or fatigue. It is
likely that the majority of single event overload fractures
occur during the explant procedure itself.
The AneuRx stent graft is designed to contain numer-
ous and redundant stent strut elements. For example, bi-
furcated stent grafts contain between 728 and 1020 of
these elements per device, and the observed rate of stent
fractures has been very small. The rate of occurrence of
stent element fractures as a percentage of available stent
elements was 0.16% for the 115 explants, of which 0.13%
are fatigue fractures. An average of 2.1 fatigue fractures per
explant have been observed for the 115 explants. Fatigue
fractures have been observed in 57 of the 115 explants, with
a range of 1 to 29 fatigue fractures.
These fatigue fractures appear to be clustered in the
midaortic stent rings, generally outside the seal zones of the
bifurcated device. The majority of fatigue fractures ob-
served during explant analysis do not appear to be related to
adverse clinical outcomes; however, it appears that severe
aortic neck angulation may be associated with the develop-
ment of fatigue fractures. Patient selection and follow-up in
accordance with the instructions for use is recommended.
Graft material and suture observations. The AneuRx
stent graft includes a polyester graft material. A change in
the material was implemented after December 1997 during
the IDE clinical trial. This change to a tighter fabric weave
reduced the porosity of the graft material. We denote this
Histogram of implant duration in months (N  115).
Table IX. Commercial experience/product performance
update
AE type
US 9/28/99
to 8/30/02
International
11/97 to 8/30/02
Rupture (total) 30 13
Preoperative* 6
Perioperative 8
Postimplant 16 13
Conversion 103 38
Aneurysm-related death (any
death occurring within 30 days
of the initial treatment, a
rupture, a conversion, or any
other secondary stent graft
procedure)
78 11
Number of bifurcated devices
distributed
20,694 4714
*The preoperative ruptures occurred in patients who had a rupture prior to
inserting the AneuRx Stent Graft. The treating physician attempted rupture
treatment with the endovascular stent graft rather than open surgical repair
due to the patient’s pre-existing comorbidities, surgical risk, and emergent
circumstance.
newer version as the Reduced Porosity Material (RPM).
The original version is referred to as pre-RPM. Eighteen
of the 115 devices were made with the pre-RPM mate-
rial, and 97 of the 115 devices were made with the RPM
material.
Observations related to graft fabric include weave sep-
aration and abrasion. The RPM, with its tighter weave,
exhibits less weave separation. Weave separation and abra-
sion occur predominantly in the ipsilateral and contralateral
iliac legs. Both have also been observed, to a lesser extent,
directly below the aortic seal zone. The presence of weave
separation or abrasion is typically observed in areas of
increased vessel tortuosity.
A portion of the RPM devices could not be evaluated
for weave separation and abrasion, as they had been de-
structively analyzed when evaluated by an outside pathol-
ogy laboratory. Eighty-one of the RPM devices were eval-
uated for weave separation and abrasion. Twenty-nine of
the 81 RPM explants exhibited holes larger than 0.2 mm2,
which is the current manufacturing specification for this
graft material. An average of 1.3 holes per RPM explant
were observed. The holes in the RPM explants averaged
0.7mm2 in size, with a median size of 0.5mm2. The poten-
tial for transgraft endoleak as a result of these holes is
unclear, because the process is influenced by many factors
such as anticoagulation, tissue incorporation and healing,
pressure gradients, and collateral flow. However,
Medtronic AVE will continue to assess the potential for
clinical impact as additional explants are received.
Broken sutures have also been observed in explanted
AneuRx stent grafts. Abrasion of the suture against the
nitinol stent appears to be the primary mode of the break-
age. The breakage is typically seen at the junction (stent tip
to stent tip connection) stitches. Suture breaks do not
appear to be clustered around a specific area of the stent
graft.
A sample of explanted devices was examined for suture
breaks. Suture breaks have been observed in 12 of the 14
explants in this sample. An average of 24.6 breaks was
observed, with a median of 22 breaks. The number of
suture breaks ranged from 0 to 72 breaks. It should be
noted that the AneuRx stent graft is designed to contain
numerous and redundant suture attachment points. Bifur-
cated stent grafts contain between 1619 and 2079 sutures
per device. The observed rate of suture breakage has been
very small. For instance, in this sampling of 14 explanted
devices the rate of suture breaks as a percentage of total
sutures is less than 1.5%. Microleaks, typically through
suture attachment sites, have been observed during a small
number of explant procedures. These microleaks are typi-
cally observed during the surgical conversion when antico-
agulation is administered, the aneurysmal sac is then
opened, and finally the thrombus adhering to the sac is
disturbed.
Potential clinical consequences. Potential clinical impli-
cations associated with stent strut fatigue fracture include,
but are not limited to, incomplete seal, endoleak, device
migration, and/or vessel perforation. Potential clinical
consequences of fabric wear and/or broken sutures include
microleaks, loss of column strength, endoleaks, and aneu-
rysm enlargement. These potential clinical consequences
can often be detected and treated during regular patient
follow-up. The presence of device anomalies such as stent
fractures, graft wear, or suture breaks does not necessarily
result in adverse clinical outcomes. Some anomalies may be
the result of the device adapting to tortuous or remodeling
patient anatomy.
Table X. Sources of explanted devices
Number from
surgical conversions
Number from
autopsies following
rupture
Number from
incidental autopsy Total
From IDE clinical study (of 1193 patients enrolled) 31 1 13 45
From US commercial sales (of 20,694 bifurcated
devices distributed as of August 2002)
30 0 7 37
From commercial sales outside of the US (of 4714
bifurcated devices distributed as of August 2002)
27 0 6 33
Totals 88 1 26 115
Table XI. Reasons for explant: Primary cause as
determined by physician
Reason for explant
Number of
occurrences:
Implant
duration
1 month
Number of
occurrences:
Implant
duration
1 month
Number of
occurrences:
Total
Increase in AAA Size 0 32 32
Incidental Autopsy 8 18 26
Rupture 4 13 17
Postimplant 0 13 13
At time of implant 4 0 4
Endoleaks (Type I, Type II,
Type III, including
component separation)
0 14 14
Implantation difficulties 7 0 7
Limb occlusion 1 5 6
Aortoenteric fistula 0 3 3
Symptomatic AAA 0 2 2
Infection 0 2 2
Migration 0 3 3
Disease progression* 0 3 3
*As defined by localized dilatation of the aortic neck
Medtronic AVE is continuing to examine explanted
devices and the environment of AAA disease to further the
development of this important therapy option. If a physi-
cian has an explanted device available for analysis by
Medtronic AVE, they should contact thier local Medtronic
AVE representative for assistance with return of the device.
Section IV: Summary
The results of the US clinical trial, worldwide commer-
cial experience, and explant analyses confirm that the An-
euRx stent graft continues to be a safe and effective option
for appropriately selected patients with infrarenal abdomi-
nal aortic aneurysms.
PATIENTS FOLLOWED AND FOLLOW-UP
PERIODS
Table XII is intended to inform the reader of the
number of patients in each phase of the IDE clinical study
that have been followed at the various follow-up periods.
The following definitions are included to enable interpre-
tation.
● Patients followed: the number of patients reaching the
end of the follow-up period with a study visit form.
● Deaths: the number of death forms received at the end of
the follow-up period.
● Patients censored: the number of patients lost, termi-
nated, or of unknown status.
● Patients lost/terminated: the number of patients with a
study termination form.
● Patients not reaching follow-up: the number of patients
in which a visit is not yet expected and the number of
patients who should have a visit but don’t have a visit or
study termination form.
Table XII. Patients followed and follow-up periods
6 months 1 year 2 years 3 years 4 years 5 years
Phase I
Patients followed 36 31 25 18 8 1
Deaths* 4 7 9 12 12 14
Patients censored* 0 2 6 10 20 25
Lost/terminated 0 2 6 6 7 7
Not reaching follow-up 0 0 0 4 13 18
Phase II
Patients followed 445 412 351 230 34 0
Deaths* 19 33 66 84 103 106
Patients censored* 6 25 53 156 333 364
Lost/terminated 4 13 27 43 57 62
Not reaching follow-up 2 12 26 113 276 302
Phase III
Patients followed 630 556 332 43 0 0
Deaths* 38 56 108 125 130 130
Patients censored* 15 71 243 515 553 553
Lost/terminated 7 18 31 46 51 51
Not reaching follow-up 8 53 212 469 502 502
*Number of deaths and patients censored are cumulative
